{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:45:13Z","timestamp":1785908713234,"version":"3.56.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of transarterial chemoembolization combined with donafenib and camrelizumab (TACE+D+C) versus TACE plus donafenib (TACE+D) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with HCC complicated by PVTT diagnosed at two medical centers between December 2021 and July 2025 were enrolled and assigned to the TACE+D group and the TACE+D+C group. Propensity score matching (PSM) was performed at a 1:1 ratio with a caliper width of 0.2 standard deviations to balance baseline confounding factors, with 109 patients included in each group after matching. The primary endpoints were median overall survival (mOS) and median progression-free survival (mPFS), both calculated from the date of TACE completion. The secondary endpoints comprised objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 109 patients were enrolled in each group following PSM. In our retrospective PSM analysis, we observed that the TACE+D+C group was associated with longer mOS (15.90 vs 9.10 months,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001) and mPFS (11.20 vs 7.10 months,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001) relative to the TACE+D group. For intrahepatic lesions, the TACE+D+C group was associated with markedly higher ORR (58.72% vs 36.70%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.001) and DCR (89.91% vs 77.06%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.011). In terms of PVTT, the TACE+D+C group also presented higher ORR (42.20% vs 23.85%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.004) and DCR (77.06% vs 64.22%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.037). The incidence of AEs after TACE was similar in both groups; mild grade 1\u20132 immune-related adverse events (irAEs) unique to camrelizumab were only detected in the TACE+D+C group, with no severe grade 3\u20134 irAEs recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This retrospective PSM analysis observed a correlation between TACE+D+C triple therapy and longer survival and higher tumor response among PVTT-positive HCC patients. Given the inherent limitations of a retrospective observational design, these results cannot establish therapeutic superiority, and prospective randomized controlled trials are warranted to validate causal clinical benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1882605","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:51:23Z","timestamp":1785905483000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of transarterial chemoembolization combined with donafenib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, retrospective propensity score-matched analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Qi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Interventional Radiology, Renmin Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hezi","family":"Qing","sequence":"additional","affiliation":[{"name":"Dongguan Community Health Service Center","place":["Hanzhong, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwu","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Qinghai University Affiliated Hospital","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwu","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Renmin Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000530495","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)","volume":"12","author":"Zhou","year":"2023","journal-title":"Liver Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03029.x","article-title":"Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong","volume":"24","author":"Cheung","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2016.0059","article-title":"Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma","volume":"13","author":"Sun","year":"2016","journal-title":"Cancer Biol Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10032-2","article-title":"Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: A nationwide study","volume":"14","author":"Chen","year":"2020","journal-title":"Hepatol Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i31.4360","article-title":"Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers","volume":"25","author":"Cerrito","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)08649-x","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The Checkmate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.609322","article-title":"Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE-refractory hepatocellular carcinoma: A retrospective study","volume":"7","author":"Zheng","year":"2020","journal-title":"Front Mol Biosci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1004652","article-title":"Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience","volume":"12","author":"Luo","year":"2022","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: A randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): A randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17998\/jlc.2024.03.13","article-title":"Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide","volume":"24","author":"Kim","year":"2024","journal-title":"J Liver Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-3136","article-title":"Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy","volume":"27","author":"Zhou","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/jhc.S443779","article-title":"Efficacy and safety of transarterial chemoembolization plus donafenib with or without immune checkpoint inhibitors as the first-line treatment for unresectable hepatocellular carcinoma: A propensity score matching analysis","volume":"11","author":"Deng","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1277329","article-title":"Transarterial chemoembolization combined donafenib with\/without PD-1 for unresectable HCC in a multicenter retrospective study","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8386","article-title":"Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"B19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00534-010-0314-0","article-title":"A new classification for hepatocellular carcinoma with portal vein tumor thrombus","volume":"18","author":"Shi","year":"2011","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12092124","article-title":"Immune-targeted therapy with or without transarterial chemoembolization (TACE) for advanced hepatocellular carcinoma with portal vein tumor thrombosis (PVTT): A multicenter retrospective study","volume":"12","author":"You","year":"2024","journal-title":"Biomedicines"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.S428980","article-title":"Transarterial chemoembolization plus lenvatinib and PD-1 inhibitors for hepatocellular carcinoma with main trunk portal vein tumor thrombus: A multicenter retrospective study","volume":"10","author":"Li","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02449-6","article-title":"Evaluating the benefits of TACE combined with lenvatinib plus PD-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus","volume":"40","author":"Zou","year":"2023","journal-title":"Adv Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.200810488","article-title":"Some methods of propensity-score matching had superior performance to others: Results of an empirical investigation and Monte Carlo simulations","volume":"51","author":"Austin","year":"2009","journal-title":"Biom J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: Performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01603-0","article-title":"Donafenib: first approval","volume":"81","author":"Keam","year":"2021","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3760\/cma.j.cn112138-20230202-00049","article-title":"Chinese expert consensus on intra-arterial drug and combined drug administration for primary hepatocellular carcinoma","volume":"62","year":"2023","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20230630-01114","article-title":"Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma (2023 edition)","volume":"103","year":"2023","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: First global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.21037\/atm-2020-115","article-title":"Camrelizumab-targeting a novel PD-1 epitope to treat hepatocellular carcinoma","volume":"8","author":"Rakk\u00e9","year":"2020","journal-title":"Ann Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153619","article-title":"A combination of sorafenib, an immune checkpoint inhibitor, TACE and stereotactic body radiation therapy versus sorafenib and TACE in advanced hepatocellular carcinoma accompanied by portal vein tumor thrombus","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650394","article-title":"Combination of sorafenib, camrelizumab, transcatheter arterial chemoembolization, and stereotactic body radiation therapy as a novel downstaging strategy in advanced hepatocellular carcinoma with portal vein tumor thrombus: A case series study","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.S473676","article-title":"Feasibility and safety of the clinical outcomes of TACE combined with lenvatinib and PD-1 blockades in the treatment of hepatocellular carcinoma with portal vein tumor thrombus: A retrospective exploratory study","volume":"17","author":"Sun","year":"2024","journal-title":"Int J Gen Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.S525454","article-title":"Efficacy and safety of hepatic artery infusion chemotherapy combined with donafenib and camrelizumab in the treatment of patients with unresectable hepatocellular carcinoma: A retrospective, single-arm study","volume":"12","author":"Wu","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"B35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1358\/dot.2023.59.2.3507751","article-title":"Donafenib in hepatocellular carcinoma","volume":"59","author":"Chen","year":"2023","journal-title":"Drugs Today (Barc)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001182","article-title":"Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution","volume":"82","author":"Zhou","year":"2025","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17808","article-title":"Mechanisms of portal vein tumour thrombus formation and development in patients with hepatocellular carcinoma","volume":"27","author":"Li","year":"2023","journal-title":"J Cell Mol Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.198701","article-title":"PD-1-targeted IL-15 mutein activates CD8+ and CD4+ T cells in infection and cancer","volume":"11","author":"Pratumchai","year":"2026","journal-title":"JCI Insight"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27324","article-title":"Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"234","author":"Wang","year":"2019","journal-title":"J Cell Physiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: An update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202309_33572","article-title":"Recent advances in treatment strategies for hepatocellular carcinoma with portal vein cancer thrombus","volume":"27","author":"Tan","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"17450","DOI":"10.1038\/s41598-025-02597-5","article-title":"The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, IRAE onset, and prognosis","volume":"15","author":"Fu","year":"2025","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-020-00483-z","article-title":"Tumor diameter for hepatocellular carcinoma: Why should size matter","volume":"51","author":"Usta","year":"2020","journal-title":"J Gastrointest Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/op.20.01055","article-title":"Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors","volume":"18","author":"Krishnan","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20472","article-title":"Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma","volume":"11","author":"Pawlik","year":"2005","journal-title":"Liver Transpl"},{"key":"B48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12876-025-03749-7","article-title":"Clinical value of systemic immunoinflammatory index in predicting recurrence and metastasis in patients with primary liver cancer","volume":"25","author":"Deng","year":"2025","journal-title":"BMC Gastroenterol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1882605\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:51:37Z","timestamp":1785905497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1882605\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2026.1882605"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1882605","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1882605"}}